Imiquimod-d6

CAT: 0804-HY-B0180S-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0180S-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
Product Name Alternative
R 837-d6
UNSPSC
12352005
Target
Autophagy; HSV; SARS-CoV; Toll-like Receptor (TLR)
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Autophagy; Immunology/Inflammation
Field of Research
Cancer; Infection; Inflammation/Immunology
Solubility
10 mM in DMSO
Smiles
NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C([2H])([2H])[2H])C([2H])([2H])[2H]
Molecular Formula
C14H10D6N4
Molecular Weight
246.34
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[3]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[4]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.|[5]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products

Popular Products